| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 77,160 | 70,670 | 75,700 | 81,660 | 79,690 |
| Sales Growth | +9.18% | -6.64% | -7.30% | +2.47% | +20.94% |
| Net Income | -7,920 | -47,490 | -92,070 | -140,820 | -125,020 |
| Net Income Growth | +83.32% | +48.42% | +34.62% | -12.64% | -100.32% |
Burning Rock Biotech Ltd ADR (BNR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Burning Rock Biotech Limited focuses on the application of next generation sequencing technology in the field of precision oncology. Its business consists of NGS-based therapy selection testing for late-stage cancer patients as well as NGS-based cancer early detection. Burning Rock Biotech Limited is based in GUANGZHOU, China.
Fiscal Year End Date: 12/31